Vampire Bat Saliva Compound Could Help Treat Strokes

Join Our Community of Science Lovers!

On supporting science journalism

If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today.

The average person wouldn't want to be bitten by a vampire bat. But the animal's saliva may one day give some stroke sufferers a better chance of survival. According to a report published online today by Stroke: Journal of the American Heart Association, vampire bat saliva contains a potent clot-busting substance that could help a greater number of patients than current medications do.

Scientists identified the medicinally promising bat compound, an enzyme known as desmoteplase or DSPA, more than a decade ago. The substance's true function--to thin a vampire victim's blood so that it flows freely, allowing the bat to feed--also makes it a candidate for treating strokes. During an ischemic stroke one or more clots block the supply of blood to the brain. Previous research had shown that DSPA is more active than the currently FDA-approved clog-busting drug rt-PA when exposed to fibrin (an insoluble protein that makes up the framework of blood clots). Because rt-PA can also cause brain damage, it must be administered within three hours of stroke onset and is thus only prescribed to a small percentage of patients. To test DSPA's effect on brain cells, Robert L. Medcalf of Monash University in Australia and his colleagues injected the brains of mice with both DSPA and rt-PA. They found that DSPA attacked fibrin, but did not act upon two brain receptors known to promote brain damage. The scientists therefore suggest that DSPA could be administered up to nine hours after stroke onset without adverse effects.

Although the results are encouraging, the study focused mainly on toxicity, cautions Larry Goldstein of the American Stroke Association Advisory Committee. "Whether this approach will prove either safe or efficacious in improving stroke outcomes requires further testing." According to the American Heart Association, human trials of DSPA are currently underway in Europe, Asia and Australia.

It’s Time to Stand Up for Science

If you enjoyed this article, I’d like to ask for your support. Scientific American has served as an advocate for science and industry for 180 years, and right now may be the most critical moment in that two-century history.

I’ve been a Scientific American subscriber since I was 12 years old, and it helped shape the way I look at the world. SciAm always educates and delights me, and inspires a sense of awe for our vast, beautiful universe. I hope it does that for you, too.

If you subscribe to Scientific American, you help ensure that our coverage is centered on meaningful research and discovery; that we have the resources to report on the decisions that threaten labs across the U.S.; and that we support both budding and working scientists at a time when the value of science itself too often goes unrecognized.

In return, you get essential news, captivating podcasts, brilliant infographics, can't-miss newsletters, must-watch videos, challenging games, and the science world's best writing and reporting. You can even gift someone a subscription.

There has never been a more important time for us to stand up and show why science matters. I hope you’ll support us in that mission.

Thank you,

David M. Ewalt, Editor in Chief, Scientific American